FB23 ‐2 and Cisplatin Synergize to Inhibit Head and Neck Squamous Cell Carcinoma by Targeting the XPF / ERCC1 Complex
Cancer Science · 2026
DOI: 10.1111/cas.70322 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2026. Verfasst von Yaoqi Jiang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral and Maxillofacial Surgery, Hospital of Stomatology, Guanghua School of Stomatology, Sun Yat-Sen University, Guangzhou, China. Hauptthemen laut MEDLINE: Cisplatin, Head and Neck Neoplasms, Squamous Cell Carcinoma of Head and Neck, DNA-Binding Proteins. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Sun Yat-sen University Clinical Research 5010 Program.
Abstract (Originalsprache)
Head and neck squamous cell carcinoma (HNSCC) is a highly aggressive malignancy with a poor prognosis, often necessitating multimodal treatment approaches. While cisplatin (CDDP) remains the first‐line chemotherapeutic agent, treatment failure frequently occurs due to drug resistance. To address this challenge, the FTO inhibitor FB23‐2 has emerged as a promising candidate to enhance therapeutic efficacy. Consequently, this study aims to evaluate the combined efficacy of CDDP and FB23‐2 in HNSCC and investigate their synergistic mechanisms. Using CCK‐8 assays, colony formation assays, and flow cytometry for proliferation and cell cycle analysis, we observed that the CDDP‐FB23‐2 combination synergistically suppressed HNSCC proliferation. This treatment induced S/G2 phase cell cycle arrest and subsequent mitotic catastrophe. We further validated these findings in vivo using 4NQO‐induced HNSCC mouse models. Additionally, drug safety was assessed via H&E staining of visceral organs, which revealed that a semi‐combined regimen reduced treatment‐related side effects. Mechanistic investigations involving immunofluorescence (IF), quantitative real‐time PCR (qRT‐PCR), co‐immunoprecipitation (Co‐IP), and western blot analyses demonstrated that FB23‐2 potentiated CDDP‐induced DNA damage while inhibiting DNA repair mechanisms, thereby promoting apoptotic cell death. Specifically, FB23‐2 blocked the assembly and nuclear translocation of XPF/ERCC1 complexes in CDDP‐treated cells, directly increasing cellular sensitivity to CDDP. Collectively, our findings demonstrate that FB23‐2 enhances CDDP sensitivity in HNSCC by targeting the XPF/ERCC1 complex, providing a theoretical basis and experimental support for their clinical application in HNSCC treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oral and Maxillofacial Surgery, Hospital of Stomatology, Guanghua School of Stomatology, Sun Yat-Sen University, Guangzhou, China.
- Guangdong Provincial Key Laboratory of Stomatology, Guanghua School of Stomatology, Sun Yat-Sen University, Guangzhou, China.
ORCID-Profile: Jinsong Hou
Förderung
- National Natural Science Foundation of China
- Sun Yat-sen University Clinical Research 5010 Program
Zitieren
APA
Jiang, Y., Cai, H., Zhu, Y., Liang, J., Li, H., Song, F., Wang, Z., & Hou, J. (2026). FB23 ‐2 and Cisplatin Synergize to Inhibit Head and Neck Squamous Cell Carcinoma by Targeting the XPF / ERCC1 Complex. Cancer Science. https://doi.org/10.1111/cas.70322
Vancouver
Jiang Y, Cai H, Zhu Y, Liang J, Li H, Song F, et al. FB23 ‐2 and Cisplatin Synergize to Inhibit Head and Neck Squamous Cell Carcinoma by Targeting the XPF / ERCC1 Complex. Cancer Science. 2026. doi:10.1111/cas.70322
BibTeX
@article{Jiang2026,
author = {Jiang, Yaoqi and Cai, Hongshi and Zhu, Yue and Liang, Jianfeng and Li, Hongyu and Song, Fan and Wang, Ziyi and Hou, Jinsong},
title = {FB23 ‐2 and Cisplatin Synergize to Inhibit Head and Neck Squamous Cell Carcinoma by Targeting the XPF / ERCC1 Complex},
journal = {Cancer Science},
year = {2026},
doi = {10.1111/cas.70322}
}
EUVIMED